| PubMed | Title | Journal | Year | Linked by |
|---|
| PMID 41467787 | Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against the Ebola virus. | mBio | 2026 | name in abstract: Ervebo |
| PMID 41519695 | Access to licenced vaccines for high-threat infectious diseases: a scoping review and interpretive analysis of Ebola virus disease. | BMC infectious diseases | 2026 | name in abstract: Ervebo |
| PMID 41526916 | Understanding perceptions towards COVID-19 vaccination and strategies to increase vaccine uptake among Ebola- affected communities in North Kivu, Democratic Republic of the Congo: a qualitative study. | BMC public health | 2026 | name in abstract: rVSV-ZEBOV |
| PMID 41634853 | Marburg and Sudan virus outbreaks: are we any closer to a pan-filovirus vaccine? | Tropical diseases, travel medicine and vaccines | 2026 | name in abstract: rVSV-ZEBOV |
| PMID 41746065 | Global Health Preparedness Frameworks and Recombinant Vaccine Platforms: A Public Health Perspective on Regulations and System Readiness. | Vaccines | 2026 | name in abstract: rVSV-ZEBOV |
| PMID 41819639 | Glycoprotein-specific transcriptional response contributes to differential vaccine protection against lethal Ebola virus infection. | Vaccine | 2026 | name in abstract: Ervebo |
| PMID 41874168 | In vitro cellular tropism and immunomodulatory response to rVSVΔG-ZEBOV-GP in human cells derived from tissues associated with adverse events. | Microbiology spectrum | 2026 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 41911664 | Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance. | Emerging infectious diseases | 2026 | name in title: Ervebo |
| PMID 42221441 | [Post-exposure prophylaxis against Ebola virus: arguments for expanding the role of monoclonal antibodies in a context of limited access]. | Medecine tropicale et sante internationale | 2026 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 42245043 | Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines. | medRxiv : the preprint server for health sciences | 2026 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 42376411 | Ebola virus disease: A persistent challenge in global health security. | Open veterinary journal | 2026 | name in abstract: rVSV-ZEBOV |
| PMID 42476156 | Reconsidering the rVSVΔG-ZEBOV-GP vaccine during the 2026 Bundibugyo virus outbreak. | The Lancet. Infectious diseases | 2026 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 42542607 | Closing Critical Gaps in the 2026 Bundibugyo Ebola Response: Five Actionable Priorities. | Cureus | 2026 | name in abstract: rVSV-ZEBOV |
| PMID 42623404 | Multiplex pan-filovirus assay performance and reproducibility across varied geographical and resource settings. | PloS one | 2026 | name in abstract: Ervebo |
| PMID 42641631 | Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus-Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: a longitudinal cohort study. | Lancet (London, England) | 2026 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 42685736 | Ring and community vaccination for Bundibugyo virus outbreak response: a stochastic network modelling study. | The Lancet. Infectious diseases | 2026 | name in abstract: rVSV-ZEBOV |
| PMID 42697215 | Cross-reactive Bundibugyo antibody responses in Guinean survivors of Ebola virus and recipients of rVSVΔG-ZEBOV-GP (Ervebo) in an outbreak setting. | The Lancet. Infectious diseases | 2026 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 42721983 | rVSVΔG-ZEBOV-GP vaccine-induced seroreactivity to Bundibugyo virus: a cross-protection dilemma. | Lancet (London, England) | 2026 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 42728358 | The 2026 Bundibugyo Ebola Outbreak: A Warning for Global Preparedness for Future Epidemics. | Iranian biomedical journal | 2026 | name in abstract: rVSV-ZEBOV |
| PMID 42742181 | Post-exposure prophylaxis with a monoclonal antibody cocktail after Bundibugyo ebolavirus exposure in adults and children. | Nature medicine | 2026 | name in abstract: rVSV-ZEBOV |
| PMID 42776645 | Ebola Virus Disease in the Era of One Health and Global Preparedness: Evolving Epidemiology, Genomic Surveillance, and Future Challenges. | Infectious disease reports | 2026 | name in abstract: rVSV-ZEBOV |
| PMID 42859161 | From Ebola response to adaptable preparedness beyond a single virus. | Tropical medicine and health | 2026 | name in abstract: Ervebo |
| PMID 42869053 | Cross-reactive T-cell responses against BDBV in humans after rVSVΔG-ZEBOV-GP vaccination. | The Lancet. Infectious diseases | 2026 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 42869683 | rVSV-ΔG-EBOV-GP-Nipah-G (also designated PHV02) replication-competent, recombinant vesicular stomatitis virus vaccine for prevention of Nipah virus disease: Standardized template with key considerations for a risk/benefit assessment. | Vaccine | 2026 | name in abstract: Ervebo |
| PMID 42880328 | Cross-neutralisation of authentic Ebola virus and Bundibugyo virus following natural infection or Ervebo vaccination. | The Lancet. Infectious diseases | 2026 | name in title: Ervebo |
| PMID 42887369 | Early detection of immunoglobulin A against a vaccine backbone protein enables fast, durable, and objective identification of individuals vaccinated against Ebola virus. | EBioMedicine | 2026 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 42890496 | Resurgence of Ebola in the Democratic Republic of Congo: Lessons Learned and Future Directions. | Health science reports | 2026 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 39805421 | Vaccination strategies for Ebola in the democratic republic of Congo: the WHO-Ebola modeling collaboration. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2025 | name in abstract: rVSV-ZEBOV |
| PMID 40143270 | Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model. | Viruses | 2025 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 40143273 | rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. | Viruses | 2025 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 40215567 | Corrigendum to "Knowledge, attitudes, and practices and long-term immune response after rVSVΔG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda" [Vaccine 24 (22) (2024) 126031]. | Vaccine | 2025 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 40375337 | Impact of most promising Ebola therapies on survival: a secondary analysis during the tenth outbreak in the Democratic Republic of Congo. | Virology journal | 2025 | name in abstract: rVSV-ZEBOV |
| PMID 40706506 | Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC. | Vaccine | 2025 | name in title: rVSV-ZEBOV |
| PMID 40902221 | Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3 months and 2 years. | Vaccine | 2025 | name in abstract: Ervebo |
| PMID 40966976 | Corrigendum to "Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC" [Vaccine 62 (2025) 127537]. | Vaccine | 2025 | name in title: rVSV-ZEBOV |
| PMID 41744005 | Long non-coding RNAs in response to Ebola virus vaccine-induced immunity. | Frontiers in immunology | 2025 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 37722397 | Prevention and post-exposure management of occupational exposure to Ebola virus. | The Lancet. Infectious diseases | 2024 | name in abstract: rVSV-ZEBOV |
| PMID 37766672 | Adaptation of an rVSV Ebola vaccine purification process for rapid development of a viral vaccine candidate for SARS-CoV-2. | Biotechnology journal | 2024 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 38305150 | Translational success of fundamental virology: a VSV-vectored Ebola vaccine. | Journal of virology | 2024 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 38315357 | Production and Purification of Filovirus Glycoproteins. | Methods in molecular biology (Clifton, N.J.) | 2024 | name in abstract: Ervebo |
| PMID 38340736 | Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo. | The Lancet. Infectious diseases | 2024 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 38489257 | Recent advances in the treatment of Ebola disease: A brief overview. | PLoS pathogens | 2024 | name in abstract: Ervebo |
| PMID 38662631 | Use of Ebola Vaccines - Worldwide, 2021-2023. | MMWR. Morbidity and mortality weekly report | 2024 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 38880693 | Knowledge, attitudes, and practices and long-term immune response after rVSVΔG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda. | Vaccine | 2024 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 39118744 | National burden of Ebola virus disease in Democratic Republic of the Congo: the urgency to act. | Annals of medicine and surgery (2012) | 2024 | name in abstract: rVSV-ZEBOV |
| PMID 39178865 | Assessing the real-world effectiveness of the rVSV-ZEBOV vaccine. | The Lancet. Infectious diseases | 2024 | name in title: rVSV-ZEBOV |
| PMID 39178866 | Effectiveness of rVSV-ZEBOV vaccination during the 2018-20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study. | The Lancet. Infectious diseases | 2024 | name in title: rVSV-ZEBOV |
| PMID 39511527 | rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches). | BMC medicine | 2024 | name in title: rVSV-ZEBOV |
| PMID 39693543 | Ebola Outbreak Response in the DRC with rVSV-ZEBOV-GP Ring Vaccination. | The New England journal of medicine | 2024 | name in title: rVSV-ZEBOV |
| PMID 39749221 | New reverse sum Revan indices for physicochemical and pharmacokinetic properties of anti-filovirus drugs. | Frontiers in chemistry | 2024 | name in abstract: Ervebo |
| PMID 35169298 | Self-replicating vehicles based on negative strand RNA viruses. | Cancer gene therapy | 2023 | name in abstract: Ervebo |
| PMID 36154608 | Gene Therapy Cargoes Based on Viral Vector Delivery. | Current gene therapy | 2023 | name in abstract: Ervebo |
| PMID 36992407 | Viral Vectors in Gene Therapy: Where Do We Stand in 2023? | Viruses | 2023 | name in abstract: Ervebo |
| PMID 37061918 | Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates. | Cell reports | 2023 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 37171813 | A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus. | The Journal of infectious diseases | 2023 | name in abstract: Ervebo |
| PMID 37243081 | Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV. | Vaccines | 2023 | name in title: rVSV-ZEBOV |
| PMID 37290053 | A Recombinant Vesicular Stomatitis Virus-Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection. | The Journal of infectious diseases | 2023 | name in abstract: Ervebo |
| PMID 37661067 | Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability. | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2023 | name in abstract: rVSV-ZEBOV |
| PMID 38022684 | Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts. | Frontiers in immunology | 2023 | name in abstract: Ervebo |
| PMID 38162033 | Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP. | iScience | 2023 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 38235127 | Refined innate plasma signature after rVSVΔG-ZEBOV-GP immunization is shared among adult cohorts in Europe and North America. | Frontiers in immunology | 2023 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 34914048 | Design of Replication-Competent VSV- and Ervebo-Vectored Vaccines Against SARS-CoV-2. | Methods in molecular biology (Clifton, N.J.) | 2022 | name in title: Ervebo |
| PMID 35012339 | Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine. | mBio | 2022 | name in abstract: rVSV-ZEBOV |
| PMID 35110410 | Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo. | Proceedings of the National Academy of Sciences of the United States of America | 2022 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 35202354 | Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021. | MMWR. Morbidity and mortality weekly report | 2022 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 35544042 | Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study. | The Lancet. Microbe | 2022 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 35545650 | Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach. | Scientific reports | 2022 | name in abstract: Ervebo |
| PMID 35622847 | A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. | PLoS neglected tropical diseases | 2022 | name in abstract: Ervebo |
| PMID 35759511 | Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. | PLoS pathogens | 2022 | name in abstract: Ervebo |
| PMID 35866579 | Safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: experience from a French pre-travel clinic. | Journal of travel medicine | 2022 | name in title: rVSV-ZEBOV |
| PMID 36091016 | Multimerization of Ebola GPΔmucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies. | Frontiers in immunology | 2022 | name in abstract: rVSV-ZEBOV |
| PMID 36146524 | Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines. | Vaccines | 2022 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 33417593 | Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. | MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports | 2021 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 33498214 | Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine. | Vaccines | 2021 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 33501447 | Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine. | bioRxiv : the preprint server for biology | 2021 | name in abstract: rVSV-ZEBOV |
| PMID 33536172 | Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. | Journal of virology | 2021 | name in abstract: rVSV-ZEBOV |
| PMID 33594388 | Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine. | Drugs of today (Barcelona, Spain : 1998) | 2021 | name in abstract: Ervebo |
| PMID 33668698 | Development of Pandemic Vaccines: ERVEBO Case Study. | Vaccines | 2021 | name in title: Ervebo |
| PMID 33719915 | High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. | Emerging microbes & infections | 2021 | name in abstract: Ervebo |
| PMID 33782211 | Effects of Gamma Irradiation of Human Serum Samples from rVSVΔG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays. | The American journal of tropical medicine and hygiene | 2021 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 33795759 | Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO. | Scientific reports | 2021 | name in title: Ervebo |
| PMID 33837958 | Bioreactor production of rVSV-based vectors in Vero cell suspension cultures. | Biotechnology and bioengineering | 2021 | name in abstract: rVSV-ZEBOV |
| PMID 33873076 | Ebola virus disease: current vaccine solutions. | Current opinion in immunology | 2021 | name in abstract: rVSV-ZEBOV |
| PMID 33937326 | Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19. | Frontiers in molecular biosciences | 2021 | name in abstract: Ervebo |
| PMID 34013349 | Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein. | The Journal of infectious diseases | 2021 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 34270366 | Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis. | Human vaccines & immunotherapeutics | 2021 | name in abstract: rVSVΔG-ZEBOV-GP |
| PMID 34335620 | Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. | Frontiers in immunology | 2021 | name in abstract: rVSV-ZEBOV |
| PMID 34343363 | Conserved immunogenic peptides of Ebola glycoprotein elicit immune response in human peripheral blood mononuclear cells. | Microbiology and immunology | 2021 | name in abstract: Ervebo |
| PMID 34535490 | 'Learn from the lessons and don't forget them': identifying transferable lessons for COVID-19 from meningitis A, yellow fever and Ebola virus disease vaccination campaigns. | BMJ global health | 2021 | name in abstract: rVSV-ZEBOV |
| PMID 34696295 | Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer. | Vaccines | 2021 | name in abstract: Ervebo |
| PMID 34749265 | Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity. | Current opinion in virology | 2021 | name in abstract: Ervebo |
| PMID 35544244 | Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials. | The Lancet. Microbe | 2021 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 31784751 | Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2020 | name in title: rVSV-ZEBOV |
| PMID 31979026 | Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas. | Vaccines | 2020 | name in title: rVSV-ZEBOV |
| PMID 32006630 | Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X™ hydro fixed-bed. | Journal of biotechnology | 2020 | name in title: rVSV-ZEBOV |
| PMID 32030996 | Safety, immunogenicity and risk-benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I-III clinical trials across regions. | Future microbiology | 2020 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 32081445 | Examination of the effect of agitation on the potency of the Ebola Zaire vaccine rVSVΔG-ZEBOV-GP. | Vaccine | 2020 | name in title: rVSVΔG-ZEBOV-GP |
| PMID 32195130 | Titration methods for rVSV-based vaccine manufacturing. | MethodsX | 2020 | name in abstract: rVSV-ZEBOV |
| PMID 32210083 | Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV. | Vaccines | 2020 | name in abstract: Ervebo |
| PMID 32243796 | A Vaccine against Ebola Virus. | Cell | 2020 | name in abstract: Ervebo |